Quantity (mg or Unit) Unit Price ($/mg or $/Unit) Final Price 100 $44.55 Total: $4,455.00 50 $51.48 Total: $2,574.00 25 $60.39 Total: $1,509.75 10 $71.28 Total: $712.80 5 $84.15 Total: $420.75

Novel anti-thrombosis agent, orally inhibiting venous thrombosis and arterial thrombosis in vivo, showing no bleeding risk

Novel lysophosphatidic acid receptor 3 (LPA3) agonist

Orphan nuclear receptor DAF-12 ligand, inhibiting the dauer-promoting activity of DAF-12

Novel water-sensitive probe, demonstrating superior sensitivity for detecting modulation of water microsolvation, structural conformation during oligomer formation and 5FUrd binding to both wild type and mutant SOD1

Building Block

Negative control for RSL3

Potent antagonist of GluN2B-NMDA receptors (Ki = 5.8 nM), inhibiting ion flux in two-electrode voltage clamp experiments (IC50 = 223 nM)

Novel prodrug of the sigma (σ) ligand haloperidol metabolite II conjugated with the histone deacetylase (HDAC) inhibitor valproic acid, demonstrating antiangiogenic activity

Novel profluorescent RAMOSUS3 (RMS3) probe with strigolactone-like bioactivity

Potent and selective 5-HT2 serotonin receptor agonist

Inhibitor of ADP-induced platelet aggregation; anti-thrombotic

Novel potassium channel opener

Novel angiogenesis inhibitor, regulating endothelial cell fate and angiogenesis

Novel probe for mycobacterial and fungal carbonic anhydrase

Catecholamine-depleting agent, actively against the 3 major monoamines in the CNS

Novel potent anti-malarial agent against multiple resistant strains of P. falciparum in vitro and show no cytotoxicity to mammalian cells

A potent and selective Adenosine receptor A2A agonist

A highly potent, selective and orally bioavailable trace amine-associated receptor 1 (TRRA1) full agonist with EC50 of 18 nM, >500-fold selectivity over human adrenergic α2A receptor.

LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.

JMV 2959 (AEZS-123) is a potent ghrelin receptor (GHS-R1A) antaognist with binding IC50 of 32 nM.

Netarsudil (AR-13324) is a potent, selective ROCK inhibitor with Ki of 4.2 nM for ROCK2.

Birinapant (TL32711) is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM, less potent to XIAP.

Presatovir (GS-5806) is a novel, orally bioavailable RSV fusion inhibitor with mean EC50 of 0.43 nM against a panel of 75 RSV A and B clinical isolates.

EPZ-005687 is a potent and selective inhibitor of EZH2 with Ki of 24 nM, 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.

DBCO intermidate 3 is a Click Chemistry intermidate used for antibody-drug conjugates..

CMS121 is a substituted quinoline that has neuroprotective, anti-inflammatory, antioxidative, and renoprotective activities.

Histrelin is a synthetic gonadotropin-releasing hormone (GNRH) agonist that binds to the GNRH receptor (GNRHR; Ki = 0.2 nM in CHO cells expressing the human receptor).

4-Butylresorcinol is a potent inhibitor of tyrosinase and is used in cosmetics as a depigmenting agent.

Antiviral activity against Varicella Zoster